Cargando…
Herpes zoster vaccination in Australia: what’s available and who benefits?
Acute herpes zoster and associated postherpetic neuralgia is caused by reactivation of latent varicella zoster virus. It can be debilitating for older adults and interfere with activities of daily living A live, attenuated single-dose vaccine, that protects against both acute herpes zoster and posth...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026919/ https://www.ncbi.nlm.nih.gov/pubmed/32139955 http://dx.doi.org/10.18773/austprescr.2020.001 |
_version_ | 1783498762548674560 |
---|---|
author | Jayasinghe, Sanjay Sheridan, Sarah Macartney, Kristine |
author_facet | Jayasinghe, Sanjay Sheridan, Sarah Macartney, Kristine |
author_sort | Jayasinghe, Sanjay |
collection | PubMed |
description | Acute herpes zoster and associated postherpetic neuralgia is caused by reactivation of latent varicella zoster virus. It can be debilitating for older adults and interfere with activities of daily living A live, attenuated single-dose vaccine, that protects against both acute herpes zoster and postherpetic neuralgia, is available for free to all Australians aged 70 years, and in a catch-up program for those aged 71–79 years The vaccine is contraindicated in people who are immunocompromised, but can be considered in those who are receiving low doses of selected disease-modifying antirheumatic drugs Records of the Australian Immunisation Register suggest that only a third of 70 year olds received the vaccine in the first year-and-a-half of the program. This is likely an underestimation, but emphasises the importance of ensuring the vaccine is offered to all eligible patients and that vaccination is recorded on the Register A non-live recombinant herpes zoster vaccine has recently been developed which is more efficacious than the live vaccine in clinical trials. It is registered in Australia but not currently available |
format | Online Article Text |
id | pubmed-7026919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | NPS MedicineWise |
record_format | MEDLINE/PubMed |
spelling | pubmed-70269192020-03-05 Herpes zoster vaccination in Australia: what’s available and who benefits? Jayasinghe, Sanjay Sheridan, Sarah Macartney, Kristine Aust Prescr Article Acute herpes zoster and associated postherpetic neuralgia is caused by reactivation of latent varicella zoster virus. It can be debilitating for older adults and interfere with activities of daily living A live, attenuated single-dose vaccine, that protects against both acute herpes zoster and postherpetic neuralgia, is available for free to all Australians aged 70 years, and in a catch-up program for those aged 71–79 years The vaccine is contraindicated in people who are immunocompromised, but can be considered in those who are receiving low doses of selected disease-modifying antirheumatic drugs Records of the Australian Immunisation Register suggest that only a third of 70 year olds received the vaccine in the first year-and-a-half of the program. This is likely an underestimation, but emphasises the importance of ensuring the vaccine is offered to all eligible patients and that vaccination is recorded on the Register A non-live recombinant herpes zoster vaccine has recently been developed which is more efficacious than the live vaccine in clinical trials. It is registered in Australia but not currently available NPS MedicineWise 2020-02-03 2020-02 /pmc/articles/PMC7026919/ /pubmed/32139955 http://dx.doi.org/10.18773/austprescr.2020.001 Text en (c) NPS MedicineWise 2020 http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License. |
spellingShingle | Article Jayasinghe, Sanjay Sheridan, Sarah Macartney, Kristine Herpes zoster vaccination in Australia: what’s available and who benefits? |
title | Herpes zoster vaccination in Australia: what’s available and who benefits? |
title_full | Herpes zoster vaccination in Australia: what’s available and who benefits? |
title_fullStr | Herpes zoster vaccination in Australia: what’s available and who benefits? |
title_full_unstemmed | Herpes zoster vaccination in Australia: what’s available and who benefits? |
title_short | Herpes zoster vaccination in Australia: what’s available and who benefits? |
title_sort | herpes zoster vaccination in australia: what’s available and who benefits? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026919/ https://www.ncbi.nlm.nih.gov/pubmed/32139955 http://dx.doi.org/10.18773/austprescr.2020.001 |
work_keys_str_mv | AT jayasinghesanjay herpeszostervaccinationinaustraliawhatsavailableandwhobenefits AT sheridansarah herpeszostervaccinationinaustraliawhatsavailableandwhobenefits AT macartneykristine herpeszostervaccinationinaustraliawhatsavailableandwhobenefits |